TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Is age 18 years old or older Satisfies the 1987 American College of Rheumatology revised criteria for Rheumatoid arthritis Has active disease at the time of randomization as indicated by a DAS28\> 5.1 Has a disease at least refractory to DMARDs whose methotrexate or leflunomide Is capable of understanding and signing an informed consent form Agrees to use a medically accepted form of contraception during the study~Exclusion Criteria:~* Is pregnant or breast-feeding or without contraception Has significant concurrent medical diseases including cancer or a history of cancer within 5 years of entering the study, uncompensated congestive heart failure, significant active infection or any underlying diseases that could predispose subjects to infections (whose tuberculosis) Has renal disease (creatinin clearance level \< 30 ml/min) Has allergy to anakinra Has leukopenia (white blood cells \< 1.5 x 109 /l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Micromechanical Modeling Using Low Magnitude Mechanical Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females, ages 45-65 years and post menopausal, as defined by a history of amenorrhea for a minimum of 24 months and a serum FSH (follicle-stimulating hormone) concentration of 25 mIU/mL (milli-International unit per milliliter) and negative pregnancy test.~Exclusion Criteria:~* Current or prior use of medications known to affect bone (e.g. bisphosphonates, calcitonin, selective estrogen receptor modulators, denosumab, diphenylhydantoin, recent systemic glucocorticoid use), bone mineral density T score of less than -2.5 and greater than +2, Vitamin D level less then 12 ng/ml, BMI (body mass index) of greater than 32, current alcohol or drug abuse: more than 3 alcoholic beverages per day or current abuse of illicit drugs or prescription medication, uncontrolled or untreated cardiac or pulmonary disease liver disease: history of hepatitis or ALT (alanine aminotransferase) or AST (aspartate aminotransferase) greater than 2x ULN (upper limit of normal), renal disease: history of renal disease or serum creatinine greater than 2x ULN diabetes, pacemaker or metallic implants considered a contraindication to MR scanning.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Low Magnitude Mechanical Stimulation (Type: EXPERIMENTAL): 10 minutes daily of 30 Hz/0.3g stimulation using a vibrating platform.
- Sham Low Magnitude Mechanical Stimulation (Type: PLACEBO_COMPARATOR): 10 minutes daily of placebo treatment using a sham vibrating platform.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency of Depression in Rheumatoid Arthritis (RA) Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* VADERA I: Participants diagnosed with RA, who did not suffer from a concurrent, manifest depressive disorder and had been scheduled for a RA consultation at one of the participating clinics~* VADERA II: All participants diagnosed with RA who were able to complete the questionnaires and had been scheduled for a RA consultation at one of the participating clinics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VADERA I (Type: None): RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 \[12 ± 2 weeks\]) with a 10-14 week interval between assessments.
- VADERA II (Type: None): All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with TIA~* Three months post-TIA~* Ability to understand the process and instructions for exercise training and provide informed consent~Exclusion Criteria:~* Resting Blood Pressure greater than 160/100 despite medication~* Other cardiovascular morbidity which would limit exercise tolerance (heart failure, abnormal BP responses or STsegment depression \> 2 mm, symptomatic aortic stenosis, complex arrhythmias)~* Current and extensive exercise participation~* Hypertrophic Cardiomyopathy~* Unstable Angina~* Orthostatic BP decrease of \> 20 mm Hg with symptoms~* Other musculoskeletal impairments which would limit the participants ability to walk sufficient durations~* Pain or other co-morbidities (e.g., unclipped aneurysms, uncontrolled seizures etc.) which would preclude participation~* Cognitive or behavioural issues that would limit participation in exercise testing and training

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Exercise (Type: None): Following a 3 month non intervention period, participants will participate in Cardiac Rehabilitation, carrying out an exercise program which will last 6 months and combine both resistance and aerobic training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed untreated primary CNS lymphoma (PCNSL) confirmed by 1 of the following methods:~  * Brain biopsy or resection~    * Patients diagnosed with T-cell PCNSL allowed but will not receive rituximab on study~ * Cerebrospinal fluid (CSF) cytology~    * Positive CSF cytology with or without measurable intracranial disease~ * Vitreal biopsy~    * Histologic confirmation of vitreal lymphoma with measurable intracranial tumor~* No evidence of systemic non-Hodgkin's lymphoma~  * CT scan of chest, abdomen, and pelvis or bone marrow biopsy negative for extracerebral source of lymphoma~* No evidence of pleural effusions or ascites~* MRI of brain and spine (plus gadolinium) must have measurable contrast enhancing disease unless CSF cytology is positive~PATIENT CHARACTERISTICS:~* Karnofsky performance score 50-100%~* HIV negative~* Creatinine clearance ≥ 50 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* No concurrent salicylates, nonsteroidal anti-inflammatory drugs, sulfonamides, or penicillins within the past week

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methotrexate, leucovorin calcium, rituximab, and temozolomide (Type: EXPERIMENTAL): Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have human leukocyte antigen (HLA)-A\*24:02~* Patients who have histologically-confirmed colorectal cancer (adenocarcinoma)~* Patients with advanced or relapsed colorectal cancer who are refractory or intolerant to standard chemotherapy~* Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1 at the time of enrollment in the trial.~Exclusion Criteria:~* Patients who are HIV antibody test positive~* Patients with an active infection~* Patients who have or are suspected to have CNS metastasis of colon cancer (such as metastatis of the brain)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose level 1 (Type: EXPERIMENTAL): None
- Dose level 2 (Type: EXPERIMENTAL): None
- Dose level 3 (Type: EXPERIMENTAL): None
- Dose level 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dysport® Pediatric Lower Limb Spasticity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 2 to 17 years with cerebral palsy~* Equinus foot position~* Ambulatory~* Intensity of muscle tone equal to or greater than 2 in affected lower limb, as measured on the Modified Ashworth Scale~Exclusion Criteria:~* Fixed contracture~* Previous phenol, alcohol injection or surgical intervention~* Other neurological / neuromuscular disorder~* Severe athetoid or dystonic movements

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Dysport 10 U/Kg (Type: EXPERIMENTAL): 10 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
- Dysport 15 U/Kg (Type: EXPERIMENTAL): 15 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
- Placebo (Type: PLACEBO_COMPARATOR): Total volume to be injected per lower limb - 2ml. Either one or both lower limbs can be treated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Attachment and Biobehavioral Catch-up for Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Mothers between 18 and 50 years of age with heightened depressive symptoms as determined by a score of 16 or higher on the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)~2. Biological children (of mothers described above) between 2 and 4 years old with heightened internalizing symptoms as determined by a T-score of 60 or higher on the Childhood Behavior Checklist (CBCL)~Exclusion Criteria:~* Self-reported history of psychosis or active suicidality as defined by self-report of a specific suicide plan or recent attempt~* Current pregnancy~* Child diagnosis of autism~* Pacemaker implant, cardiac problems, cardiac medication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- ABC (Type: EXPERIMENTAL): ABC delivers therapy through 10, home-based, in-person sessions led by a trained professional. Treatment content is based on attachment theory and an understanding of children's stress neurobiology. Components aim to improve parental sensitivity, nurturance, and responsivity, as well as children's biological and behavioral reactivity through dyadic interactions between parents and children.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of IDN-6556 in Subjects With Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and able to understand and willing to comply with the requirements of the study~* Clinical, radiological, or biochemical evidence of liver cirrhosis~* Model for End-Stage Liver Disease (MELD) Score of 11 to 18 during the Screening period~* Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from Screening to one month after the last dose of study drug.~Exclusion Criteria:~* Known infection with human immunodeficiency virus (HIV)~* Auto-immune hepatitis~* Subjects with evidence of uncontrolled infection, defined as persistent bacterial culture positivity despite adequate antibiotic therapy~* HCV infected subjects who are receiving or plan to receive anti-viral therapy during the study~* Untreated esophageal varices with high risk stigmata for hemorrhage~* Variceal hemorrhage within 3 months of Screening~* Ascites not adequately controlled on stable background medication~* Other non-liver organ failure~* Child-Pugh score of 10-15 (Child-Pugh C classification)~* Use of vasoactive drugs (at or within 3 months of Screening) that may impair hepatic blood flow~* Change in dose or regimen within 3 months of Screening of:~  1. Fibrates or statins~ 2. Angiotensin II receptor antagonist or angiotensin converting enzyme (ACE) inhibitor~* Use of chronic anticoagulation therapy including but not limited to Vitamin K/Factor Xa antagonists/inhibitors~* Use of the following drugs within 2 months of Screening:~  1. Systemic corticosteroids~ 2. Known or suspected use of illicit drugs or drugs of abuse (allowed if medically prescribed or indicated)~* Concomitant pancreatitis~* Active inflammatory bowel disease~* Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA)~* Subjects with active or history of malignancies other than hepatocellular carcinoma (HCC) within Milan criteria or curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for five or more years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDN-6556 (Type: EXPERIMENTAL): 25 mg BID of IDN-6556
- Placebo (Type: PLACEBO_COMPARATOR): Placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criterion:~* Older individuals who are long-term AIDS survivors and suffer from moderate-to-severe demoralization.~Exclusion Criteria:~* A physical, neurological or cognitive condition that makes participating in the study unsafe or unfeasible.~* Regular psychotropic medication use.~* Personal or family history of serious mental illness.~* Severe depression requiring immediate standard-of-care treatment.~* Exclusion by the clinical judgment of the study investigators.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group therapy plus psilocybin (Type: EXPERIMENTAL): Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have provided informed consent prior to any study specific procedures.~* Participants currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder as confirmed by the Structured Clinical Interview (SCID) with a current with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration.~* Participants with normal physical examination, laboratory, vital signs, and/or echocardiogram (ECG).~* Verified previous manic or mixed episode.~* Participants with a total Hamilton Rating Scale for Depression (HAMD)-17 score ≥ 20.~* Participants with a HAMD-17 item 1 score ≥ 2.~* Participants with a Clinical Global Impression of Severity (CGI-S) score ≥ 4.~Exclusion Criteria:~* Participants with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous 6 months.~* Women who are pregnant or breast feeding~* Participants with Young Mania Rating Scale (YMRS) total score \> 10~* Participants who have dementia, mental retardation, schizophrenia/schizoaffective disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once a day for 8 weeks.
- Cariprazine 0.75 mg (Type: EXPERIMENTAL): Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
- Cariprazine 1.5 mg (Type: EXPERIMENTAL): Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
- Cariprazine 3.0 mg (Type: EXPERIMENTAL): Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TTA in Treatment of Diabetes and Dyslipidemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes mellitus with HbA1c 8.0-12.0%,~* fasting S-triacylglycerol 2.0-10.0 mmol/L,~* body mass index 25-40 kg/m2 and/or waist/hip ratio \> 0.90.~Exclusion Criteria:~* fasting total cholesterol \>10 mmol/L,~* blood pressure 170/110 mmHg~* other significant disease~* Use of any corticosteroid, anticoagulant or lipid-lowering drug 2 weeks prior to inclusion.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Single group (Type: ACTIVE_COMPARATOR): Single group all treated similarly, outcome evaluated as changes within individuals during intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis ADHD~* Total score of greater than or equal to 26 on ADHD-RS-IV~* IQ of greater than or equal to 80~* Blood pressure measurements within 95th percentile for age, gender, height at screening and baseline~Exclusion Criteria:~* Current controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis (except ODD)~* Known nonresponder to psychostimulant treatment~* BMI for age greater than 90th percentile~* History of seizures during last 2 years~* Conduct Disorder

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: ACTIVE_COMPARATOR): Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Transdermal patch, 0mg, daily for 11 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete